Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
Doctors of Moorfields Eye Hospital documented that repeated injections of a transparent gel called HPMC restored vision in 7 out of 8 patients whose eyes collapsed due to low pressure, a previously untreatable condition, with 12 months follow-up and costing pennies per dose.
A surgical gel that already exists in operating rooms of ophthalmic hospitals worldwide and costs pennies per application restored the ability to see for seven out of the eight patients who participated in a pilot study at Moorfields Eye Hospital in London. The patients had a condition called hypotony, in which the pressure inside the eye drops to such low levels that the eye structure collapses inward, the retina and lens lose alignment, and vision progressively fades. Until now, doctors informed these individuals that little could be done, and the diagnosis equated to a sentence of irreversible vision loss.
The gel used in the treatment is hydroxypropyl methylcellulose, a substance known by the acronym HPMC, a transparent material that ophthalmologists routinely use during eye surgeries to protect delicate tissues and prevent internal surfaces of the eye from sticking together. The novelty is not in the substance, but in its use: instead of applying the gel during a procedure and then removing it, the team led by ophthalmologist Harry Petrushkin injected the HPMC repeatedly every two to four weeks, keeping the eye filled long enough for the visual structures to realign and remain stable. The study was published and followed the patients over 12 months.
How the gel restores vision in collapsed eyes
The mechanism is comparable to inflating a deflated ball. When the internal pressure of the eye drops below what is necessary, the eye wall gives way, the anterior chamber becomes shallower, and the retina can develop folds that distort or eliminate vision. The gel, when injected in the correct amount, fills the lost space, pushes the walls back to their original position, and allows light to pass through the eye to the retina in an orderly manner, restoring focus.
-
A Brazilian lost his job to artificial intelligence, moved to a 28-square-meter styrofoam house in a slum in China, pays R$ 30 in rent per month, and says he feels like he is traveling every day.
-
Archaeologists were exploring a cave in Alabama when they identified a giant drawing on the ceiling that had remained invisible for centuries, and upon reconstructing it in 3D, they discovered a sacred 3-meter snake that changes the history of indigenous art in the USA.
-
Every year, artists from around the world travel to Sweden to sculpt 100 hotel rooms made entirely of ice and snow, with an internal temperature of minus 5 degrees, and guests sleep in sleeping bags on ice beds.
-
A gardener found R$ 235 thousand in gold bars hidden under the grass while mowing the lawn of a reservoir in Germany, and six months later, no one came forward to claim the treasure, so the municipality kept it all.
Petrushkin described the process straightforwardly: it is like inflating the eye to the exact size at which it can function again. The injections were repeated every two to four weeks until the volume remained stable without the need for a new dose, at which point the doctors would stop the treatment and monitor if the pressure remained adequate. The transparency of the gel is crucial for success because, unlike the silicone oil used previously, HPMC allows doctors to see through it and assess the state of the retina in real-time during follow-up.
Why the gel replaced silicone oil in treatment
Before this approach, the available option for filling eyes with low pressure was silicone oil, a thick liquid used to support fragile retinas. The problem is that prolonged use of oil can lead to increased eye pressure, corneal damage, and blurred vision that complicates medical monitoring. The HPMC gel eliminates these complications: it is transparent, allows continuous observation of the retina, and does not cause the side effects associated with silicone.
Petrushkin emphasized that the ability to see through the gel completely changes the quality of follow-up. With oil, doctors worked partially blind when trying to evaluate the interior of the treated eye. With the gel, any change in the retina, swelling, or misalignment can be detected early, allowing for quicker intervention. The replacement of an opaque substance with a transparent one is the difference that transforms treatment from guesswork to direct observation.
What patients experienced after treatment with the gel
The results at Moorfields went beyond clinical charts. Nicki Guy, a 47-year-old patient, reported that after treatment she was able to take her son skiing, an activity impossible when the vision in her left eye was compromised. The recovery of the eye’s shape reduced visual distortion and, in many cases, made vision clearer than patients had experienced in months or years.
Even with the improvement, treatment with the gel requires constant monitoring. Patients underwent frequent examinations throughout the 12 months of the study, and doctors warned that the approach does not repair already damaged optic nerves. If the disease has destroyed the nerve pathway that transmits images to the brain, filling the eye with gel recovers the shape but does not restore the vision that depended on that nerve. The selection of patients prioritized cases where the eye still had residual visual function.
The risks and limitations that the gel presented in the study
The pilot project was not without complications. In two eyes, uveitis occurred, inflammation of the eye tissues that blurred the gel until eye drops and steroid injections resolved the issue. Two other patients temporarily lost vision after an application, a problem reversed by removing the excess fluid through a fine needle, a procedure called paracentesis. All adverse events were managed, but their occurrence in such a small group at Moorfields indicates that rarer risks may arise in larger populations.
The scale of the study is the main limitation. Eight patients over 12 months provide promising but not definitive evidence, and the medical community is awaiting larger clinical trials to confirm that the gel maintains results over years and not just months. The estimate of around 100 new cases of hypotonia per year in the UK makes recruitment difficult, but researchers plan to compare different formulations of the gel and establish an application schedule that minimizes the need for frequent returns.
What the penny gel could mean for ophthalmology
If larger-scale clinical trials confirm what the Moorfields pilot study indicated, treatment with HPMC gel could transform a condition previously considered unsolvable into a manageable problem. The fact that the substance is already available in surgical rooms worldwide and costs pennies per dose eliminates the two biggest barriers that typically delay the adoption of new therapies: regulatory approval of unknown material and prohibitive costs for healthcare systems. The innovation is not in the chemistry, but in the protocol: using what already existed in a way that no one had systematically tested.
For the approximately 100 patients diagnosed per year only in the UK, and their equivalents in other countries, the gel represents the first real option for recovery. The message these patients heard before was that nothing could be done. Now, there is preliminary evidence that something as simple as filling the eye with a clear material every few weeks can restore the ability to see. Science still needs to confirm, but the path is open.
And you, did you know that a penny gel could restore vision? Do you think simple treatments like this receive less attention because they are too cheap? Share your opinion in the comments.
Seja o primeiro a reagir!